A clinical comparison between dedifferentiated low-grade osteosarcoma and conventional osteosarcoma

Abstract

Aims The purpose of this study was to clarify the clinical behaviour, prognosis, and optimum treatment of dedifferentiated low-grade osteosarcoma (DLOS) diagnosed based on molecular pathology. Patients and Methods We retrospectively reviewed 13 DLOS patients (six men, seven women; median age 32 years (interquartile range (IQR) 27 to 38)) diagnosed using the following criteria: the histological coexistence of low-grade and high-grade osteosarcoma components in the lesion, and positive immunohistochemistry of mouse double minute 2 homolog (MDM2) and cyclin-dependent kinase 4 (CDK4) associated with MDM2 amplification. These patients were then compared with 51 age-matched consecutive conventional osteosarcoma (COS) patients (33 men, 18 women; median age 25 years (IQR 20 to 38)) regarding their clinicopathological features. Results The five-year overall survival (OAS) rates in the DLOS and COS patients were 85.7% and 77.1% (p = 0.728), respectively, and the five-year progression-free survival (PFS) rates were 57.7% and 44.9% (p = 0.368), respectively. A total of 12 DLOS patients received chemotherapy largely according to regimens for COS. Among the nine cases with a histological evaluation after chemotherapy, eight showed a poor response, and seven of these had a necrosis rate of < 50%. One DLOS patient developed local recurrence and five developed distant metastases. Conclusion Based on our study of 13 DLOS cases that were strictly defined by histological and molecular means, DLOS showed a poorer response to a standard chemotherapy regimen than COS, while the clinical outcomes were not markedly different. Cite this article: Bone Joint J 2019;101-B:745–752.

<p>Upregulated lncRNA THRIL/TNF-α Signals Promote Cell Growth and Predict Poor Clinical Outcomes of Osteosarcoma</p>

“…Approximately 50% of all patients at the time of diagnosis develop metastases, which results in a high mortality rate despite improvements in radiotherapy, adjuvant chemotherapy and surgery. [1][2][3] Elucidation of the molecular basis of OS progression is conducive to developing effective therapeutic agents and improving OS patient's prognosis.…”

LncRNA SNHG15 regulates osteosarcoma progression in vitro and in vivo via sponging miR-346 and regulating TRAF4 expression

“…Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents [1], which was characterized by strong invasiveness and early metastasis [2]. Although chemotherapy regimens and neoadjuvant techniques have improved, approximately 50% of all patients have metastases at the time of diagnosis, which results in a high mortality rate [3]. Therefore, exploring the mechanism of OS is of great significance for understanding the progress of the disease and for finding potential therapeutic targets.…”

miR-509-5p Inhibits the Proliferation and Invasion of Osteosarcoma by Targeting TRIB2

“…Osteosarcoma (OS) is a highly malignant tumor occurring in children, counting for 3-5% of newly diagnosed cancers of adolescents [1]. Although the five-year survival rate has been improved to 60-75% thanks to the rapid development of treatment strategies, the prognosis remained poor for the complicated carcinogenesis of OS is still unclear [2]. erefore, it is of great urgency to seek for new biomarkers that targeted preventive and/or therapeutic interventions for OS patients to improve the clinical outcome [3,4].…”